Instillation, Drug

2 trials

Sponsors

National Center for Animal and Plant Health (CENSA), Center for Genetic Engineering and Biotechnology (CIGB)

Conditions

Acute Respiratory Distress Syndrome (ARDS) PediatricsCOVID-19 Convalescence COVID-19 SARS-CoV2

Phase 2

CIGB-Mambisa/Abdala in convalescents

Active, not recruitingRPCEC00000382

Center for Genetic Engineering and Biotechnology (CIGB)COVID-19 Convalescence COVID-19 SARS-CoV2

Start: 2021-07-13Target: 120Updated: 2026-03-30

Phase 4

Safety and effectiveness of SURFACEN® combined with the conventional therapy, in the treatment of ARDS in pediatrics. National extension

RecruitingRPCEC00000253

National Center for Animal and Plant Health (CENSA)Acute Respiratory Distress Syndrome (ARDS) Pediatrics

Start: 2017-12-11Target: 193Updated: 2026-03-30

Related Papers

Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical Trial

Vaccines2024-09-012 citations